Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003461231 | Oral cavity | NEOLP | response to tumor necrosis factor | 55/2005 | 253/18723 | 2.23e-07 | 7.28e-06 | 55 |
GO:200123532 | Oral cavity | NEOLP | positive regulation of apoptotic signaling pathway | 34/2005 | 126/18723 | 2.55e-07 | 8.23e-06 | 34 |
GO:005065731 | Oral cavity | NEOLP | nucleic acid transport | 40/2005 | 163/18723 | 3.74e-07 | 1.15e-05 | 40 |
GO:005065831 | Oral cavity | NEOLP | RNA transport | 40/2005 | 163/18723 | 3.74e-07 | 1.15e-05 | 40 |
GO:000644631 | Oral cavity | NEOLP | regulation of translational initiation | 25/2005 | 79/18723 | 3.75e-07 | 1.15e-05 | 25 |
GO:004572732 | Oral cavity | NEOLP | positive regulation of translation | 35/2005 | 136/18723 | 5.91e-07 | 1.74e-05 | 35 |
GO:005123631 | Oral cavity | NEOLP | establishment of RNA localization | 40/2005 | 166/18723 | 6.24e-07 | 1.82e-05 | 40 |
GO:007135631 | Oral cavity | NEOLP | cellular response to tumor necrosis factor | 50/2005 | 229/18723 | 6.79e-07 | 1.93e-05 | 50 |
GO:000173232 | Oral cavity | NEOLP | formation of cytoplasmic translation initiation complex | 10/2005 | 16/18723 | 8.46e-07 | 2.30e-05 | 10 |
GO:003425033 | Oral cavity | NEOLP | positive regulation of cellular amide metabolic process | 39/2005 | 162/18723 | 8.79e-07 | 2.37e-05 | 39 |
GO:001593131 | Oral cavity | NEOLP | nucleobase-containing compound transport | 48/2005 | 222/18723 | 1.51e-06 | 3.77e-05 | 48 |
GO:003320931 | Oral cavity | NEOLP | tumor necrosis factor-mediated signaling pathway | 27/2005 | 99/18723 | 3.40e-06 | 7.60e-05 | 27 |
GO:007233134 | Oral cavity | NEOLP | signal transduction by p53 class mediator | 37/2005 | 163/18723 | 7.22e-06 | 1.43e-04 | 37 |
GO:005102831 | Oral cavity | NEOLP | mRNA transport | 31/2005 | 130/18723 | 1.38e-05 | 2.43e-04 | 31 |
GO:190225331 | Oral cavity | NEOLP | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 12/2005 | 29/18723 | 1.99e-05 | 3.32e-04 | 12 |
GO:190179833 | Oral cavity | NEOLP | positive regulation of signal transduction by p53 class mediator | 11/2005 | 25/18723 | 2.21e-05 | 3.60e-04 | 11 |
GO:004324421 | Oral cavity | NEOLP | regulation of protein-containing complex disassembly | 29/2005 | 121/18723 | 2.33e-05 | 3.72e-04 | 29 |
GO:003298431 | Oral cavity | NEOLP | protein-containing complex disassembly | 45/2005 | 224/18723 | 2.33e-05 | 3.72e-04 | 45 |
GO:190179634 | Oral cavity | NEOLP | regulation of signal transduction by p53 class mediator | 24/2005 | 93/18723 | 3.18e-05 | 4.80e-04 | 24 |
GO:007233232 | Oral cavity | NEOLP | intrinsic apoptotic signaling pathway by p53 class mediator | 21/2005 | 76/18723 | 3.26e-05 | 4.86e-04 | 21 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EIF5 | SNV | Missense_Mutation | | c.39C>G | p.Phe13Leu | p.F13L | P55010 | protein_coding | deleterious(0.03) | possibly_damaging(0.558) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
EIF5 | SNV | Missense_Mutation | | c.238C>T | p.His80Tyr | p.H80Y | P55010 | protein_coding | deleterious(0) | benign(0.277) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
EIF5 | SNV | Missense_Mutation | rs779336285 | c.124G>A | p.Val42Ile | p.V42I | P55010 | protein_coding | tolerated(0.55) | benign(0.013) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
EIF5 | SNV | Missense_Mutation | | c.33N>G | p.Asp11Glu | p.D11E | P55010 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-E2-A14O-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
EIF5 | insertion | In_Frame_Ins | novel | c.321_322insTGTCTTGCAGCTTATTCGCCTCAT | p.Thr107_Asp108insCysLeuAlaAlaTyrSerProHis | p.T107_D108insCLAAYSPH | P55010 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
EIF5 | insertion | Nonsense_Mutation | novel | c.507_508insCGAGGTCAGGAGTTCTAGACCAGCCTAGCCAACAT | p.Asn170ArgfsTer6 | p.N170Rfs*6 | P55010 | protein_coding | | | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EIF5 | insertion | Nonsense_Mutation | novel | c.311_312insCGTCTGATTGCCAAGGTAATAAACTGCTCTTCAATTTAGT | p.Pro105ValfsTer2 | p.P105Vfs*2 | P55010 | protein_coding | | | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EIF5 | SNV | Missense_Mutation | novel | c.1204N>A | p.Glu402Lys | p.E402K | P55010 | protein_coding | deleterious(0.02) | benign(0.173) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
EIF5 | SNV | Missense_Mutation | novel | c.89N>G | p.Asn30Ser | p.N30S | P55010 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
EIF5 | SNV | Missense_Mutation | novel | c.173N>T | p.Gly58Val | p.G58V | P55010 | protein_coding | deleterious(0) | benign(0.267) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |